A Promising Pathway Toward Mitigation and Eradication of Coronary Artery Disease

Ronald P Karlsberg1,2,3, Geoffrey W Cho2,3, Jairo Aldana-Bitar3,4

  • 1Cedars Sinai Heart Institute, Los Angeles, CA, USA.

Cardiology Research
|December 19, 2024
PubMed

Insights

Cardiovascular disease treatment is advancing with novel strategies. Personalized, multi-pathway interventions, including plaque-directed therapy, aim to improve outcomes beyond traditional methods.

Area of Science:

  • Cardiology and cardiovascular disease research.
  • Translational medicine and therapeutic innovation.

Background:

  • Cardiovascular disease (CVD) is a leading global cause of mortality despite historical advancements in cardiology.
  • Current treatment paradigms have not sufficiently reduced CVD-related deaths, necessitating innovative approaches.

Purpose of the Study:

  • To introduce a novel, personalized treatment strategy for cardiovascular disease.
  • To explore the identification and treatment of multiple disease pathways, moving beyond traditional risk factors.

Main Methods:

  • Focus on plaque-directed therapy as a primary intervention, contrasting with traditional surrogate therapies.
  • Integration of emerging technologies like artificial intelligence in cardiac imaging and genetic testing.
  • Application of genetic silencing and personalized, multi-approach treatment modalities.

Main Results:

  • The proposed strategy aims to mitigate CVD consequences and potentially eradicate the disease.
  • Highlights the potential of personalized medicine in cardiovascular care, drawing parallels with cancer treatment protocols.

Conclusions:

  • A paradigm shift towards identifying and treating multiple CVD pathways is essential.
  • Personalized, multi-modal interventions offer a promising future for cardiovascular disease management and eradication.

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
453
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
467
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
517